Skip to main content
Top

Breast Cancer Research and Treatment

Issue 2/2001

Content (8 Articles)

Expression of E2F-1 and E2F-4 is reduced in primary and metastatic breast carcinomas*

Gay Hui Ho, Jacqueline E. Calvano, Maria Bisogna, Kimberly J. Van Zee

Early-stage breast cancer treatment among medically underserved women diagnosed in a national screening program, 1992–1995

Lisa C. Richardson, Jane Schulman, Lowell E. Sever, Nancy C. Lee, Ralph J. Coates

Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease

Carla Fiorentino, Alfredo Berruti, Alberto Bottini, Maria Bodini, Maria Pia Brizzi, Antonio Brunelli, Ugo Marini, Giovanni Allevi, Sergio Aguggini, Angela Tira, Palmiro Alquati, Lucio Olivetti, Luigi Dogliotti

Chemoprevention of DMBA-induced mammary cancer in rats by dietary soy

Daniela Gallo, Sabrina Giacomelli, Fabio Cantelmo, Gian Franco Zannoni, Gabriella Ferrandina, Erika Fruscella, Antonella Riva, Paolo Morazzoni, Ezio Bombardelli, Salvatore Mancuso, Giovanni Scambia

Adherence to recommendations for clinical follow-up after benign breast biopsy

Michael A. Andrykowski, Janet S. Carpenter, Jamie L. Studts, Matthew J. Cordova, Lauren L.C. Cunningham, Wendy Mager, David Sloan, Daniel Kenady, Patrick McGrath

Instructions for Authors

Instructions for authors

Marc Lippman

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine